Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy.

We propose that treatment with AZA activates OX40L/OX40 co-stimulatory signaling in CAR T cells. Our data suggest that the clinical use of AZA before CAR T cells could be considered.